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Deletion of aquaporin-4 in APP/PS1 mice
exacerbates brain Aβ accumulation and
memory deficits
Zhiqiang Xu1†, Na Xiao1†, Yali Chen1†, Huang Huang1, Charles Marshall2, Junying Gao1, Zhiyou Cai3, Ting Wu4,
Gang Hu1 and Ming Xiao1*

Abstract
Background: Preventing or reducing amyloid-beta (Aβ) accumulation in the brain is an important therapeutic
strategy for Alzheimer’s disease (AD). Recent studies showed that the water channel aquaporin-4 (AQP4) mediates
soluble Aβ clearance from the brain parenchyma along the paravascular pathway. However the direct evidence for
roles of AQP4 in the pathophysiology of AD remains absent.
Results: Here, we reported that the deletion of AQP4 exacerbated cognitive deficits of 12-moth old APP/PS1 mice,
with increases in Aβ accumulation, cerebral amyloid angiopathy and loss of synaptic protein and brain-derived
neurotrophic factor in the hippocampus and cortex. Furthermore, AQP4 deficiency increased atrophy of astrocytes
with significant decreases in interleukin-1 beta and nonsignficant decreases in interleukin-6 and tumor necrosis
factor-alpha in hippocampal and cerebral samples.
Conclusions: These results suggest that AQP4 attenuates Aβ pathogenesis despite its potentially inflammatory
side-effects, thus serving as a promising target for treating AD.
Keywords: Alzheimer’s disease, Amyloid-beta, Astrocytes, AQP4, Paravascular pathway

Background
Alzheimer’s disease (AD) is a common neurodegenerative disorder, characterized by progressive cognitive dysfunction. To this point, there are no effective therapeutic
strategies for this devastating disease [1]. The pathogenesis of AD remains unclear, but various mechanisms
cause an imbalance between amyloid-beta (Aβ) production and clearance. This results in increased levels of soluble Aβ and final plaque accumulation within the brain
parenchyma, which is a key step in the onset and development of AD [2]. Identifying potential pathways that
are responsible for clearance of soluble Aβ from the
brain is an important strategy for the treatment of AD.
Evidence from a series of recent experiments reveals
that the paravascular pathway facilitates the clearance of
interstitial solutes (ISF), including a large proportion of
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soluble Aβ, from the brain parenchyma [3–6]. Impairment in ISF drainage along perivascular spaces with
amyloid deposits occurs in transgenic mouse models of
AD, suggesting that improving Aβ clearance along the
paravascular pathway may provide a feasible therapeutic
approach to control the progression of AD [7].
The water channel aquaporin-4 (AQP4) is primarily
localized to perivascular astrocyte endfeet and astrocyte
membranes facing the pia mater, helping to maintain
water homeostasis in the central nervous system [8]. Altered AQP4 expression and localization in reactive astrocytes has been observed in patients with AD and
several transgenic mouse models of AD [9–12]. Furthermore, animal experiments demonstrate that AQP4 is responsible for the bulk ISF flow that drives the clearance
of interstitial Aβ from the brain parenchyma [5, 6].
These results suggest that the application of AQP4 agonists or opening agents can promote brain interstitial Aβ
clearance, and thus delay or even counter the progression of AD.
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Reactive astrogliosis surrounding amyloid plaques is
one of the neuropathological hallmarks of AD. Attenuating astrocyte activation has been shown to accelerate
plaque pathogenesis in mouse AD model [13]. Previous
studies suggested that AQP4 deficiency alters astrocyte
reactivation after traumatic brain or spinal cord injuries
and chemical agents-induced neurodegeneration [14–17].
We also found that genetic deletion of AQP4 reduces Aβinduced activation of cultured astrocytes, which is associated with a reduction in the uptake of Aβ [18]. Moreover,
AQP4 is implicated in proinflammatory features of astrocytes, which is an aggravating factor in the AD pathology
[19, 20]. Therefore, clarifying the overall role of AQP4 in
the AD pathophysiological process should be a premise
for therapeutic strategies of AD.
In this study, we successfully established AQP4 gene
knockout (AQP4−/−) Aβ precursor protein/presenilin 1
(APP/PS1) transgenic mice and demonstrated that the
deletion of AQP4 has a tendency to reduce neuroinflammation, but aggravates brain Aβ accumulation, subsequently exacerbating synaptic protein loss, astrocyte
atrophy and cognitive dysfunction in 12-month old
APP/PS1 mice.

Results
AQP4 deficiency aggravated cognitive impairment in
APP/PS1 mice

We examined the spatial learning and memory of wildtype (WT), AQP4−/−, APP/PS1 and AQP4−/−APP/PS1
mice at 12 months of age using the Morris water maze
test. These genotype mice showed different performances during the hidden platform tests (Fig. 1a). For
WT mice, the escape latency progressively decreased
over the 6 days of training. AQP4−/− mice had an easier
time finding the hidden platform during the early stage
of the training (1 day), but seemed to forgot quickly during the latter stages (3–6 days), indicating impaired
memory consolidation [21]. APP/PS1 mice exhibited impaired learning ability, compared to WT mice. Genetic
deletion of AQP4 further exacerbated cognitive impairment in APP/PS1 mice, reflected by extended escape latency during the entire training periods. Swimming
speed was equivalent among the four groups, suggesting
that their differing time spent locating the underwater
platform was unrelated to motor ability (Fig. 1b). In the
probe test, swimming paths of WT mice were highly
concentrated in the target quadrant. APP/PS1 mice and
AQP4−/− mice tended to search in a larger area of the
pool, but still preferred the target quadrant. In contrast,
AQP4−/−APP/PS1 mice frequently swam randomly in
each quadrant without any purpose (Fig. 1c). The percentage of time spent in the target quadrant, and numbers of platform area crossings in AQP4−/−APP/PS1
mice were lowest among the four groups (Fig. 1d, e).
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Genetic deletion of AQP4 exaggerating spatial memory
deficits in APP/PS1 mice was further confirmed by the
Y-maze test, with the lowest time exploring the novel
arm and the lowest numbers of the novel arm entries
during the retention trial (Fig. 1f, g).
AQP4 deficiency increased brain Aβ accumulation and
CAA in APP/PS1 mice without altering the expression
levels of proteins associated with Aβ formation and
degradation

The previous study revealed that AQP4 deficiency
impairs the clearance of intraparenchymal injection of
exogenous Aβ peptide [5]. In the present study, we addressed the long-term contribution of AQP4 to the
clearance of endogenous Aβ in APP/PS1 mouse brain.
In 12-month old AQP4−/−APP/PS1 mice, Thioflavin-S
positive fibrillar plaques and 6E10-immunopositive diffuse plaques occupied a great deal of the hippocampal
and cortical areas, compared to APP/PS1 mice (Fig. 2a,
c, d). In addition to the brain parenchyma, Aβ deposition manifested in cortical and leptomeningeal vessels
as cerebral amyloid angiopathy (CAA), which was also
increased in the AQP4−/−APP/PS1 mice (Fig. 2b, e).
Consistent with increased amyloid load, ELISA analysis
demonstrated that AQP4 deficiency increased both soluble and insoluble Aβ1–40 and Aβ1–42 levels in APP/PS1
mouse brain (Fig. 2f-i).
To further investigate the molecular mechanisms of
the effects of AQP4 deficiency on plaque pathogenesis,
we examined the expression of proteins involved in Aβ
synthesis and degradation in the cerebral cortex and
hippocampus lysates. APP is processed first by the βsecretase (β-site amyloid precursor protein-cleaving enzyme 1, BACE1) to form the soluble peptide APP β
(SAPPβ), and transmembrane peptide C-terminal fragments (CTFβ) [22]. The latter are cleaved by the γsecretase complex, including presenilin 1 (PS1), to form
Aβ peptides, which are subsequently released into the
extracellular space [22]. AQP4−/−APP/PS1 mice demonstrated significant increases in levels of Aβ1–42 and
SAPPβ, but no significant changes in APP, CTFβ, BACE1
and PS1 (Fig. 3a-d), suggesting that AQP4 gene deletion
did not affect APP production and processing, but selectively impaired clearance of its soluble proteolytic
fragments from the brain. In addition, insulin degrading
enzyme (IDE) and neprilysin (NEP), the two major Aβdegrading enzymes in the brain [23], showed no significant changes in AQP4−/−APP/PS1 mice (Fig. 3c, d)
(Additional file 1: Figure S1). Taken together, these data
indicate that AQP4 deficiency could be impair rapid
transport of water-mediated Aβ clearance from the brain
parenchyma, subsequently increasing the Aβ burden in
APP/PS1 mouse brain without altering the expression
levels of Aβ formation and degradation-related proteins.
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Fig. 1 AQP4 deficiency aggravated cognitive impairment in 12 month-old APP/PS1 mice. a The mean escape latency, and b swimming speed
during the hidden platform training period of the Morris water maze test. c Tracings of the typical swim patterns. d The percentage of time
spent in the target quadrant. e The number of crossing the platform area. f The percentage of time spent in the novel arm. g The number of
entries into the novel arm in the Y-maze. Data represent mean ± SEM from 9 to 11 mice (6–8 female, and 3–5 male) per group. Data in Fig. 1a
and b were analyzed by repeated-measures ANOVA with post hoc Student-Newman-Keuls test, *P < 0.05, AQP4−/−APP/PS1 mice vs APP/PS1 mice;
#P < 0.05, APP/PS1 mice vs WT mice; ^P < 0.05, AQP4−/− mice vs WT mice. Data in Fig. 1d-g were analyzed by ANOVA with post hoc StudentNewman-Keuls test. *P < 0.05; **P < 0.01; ***P < 0.001

AQP4 deficiency accelerated the progression of astrocyte
pathology in APP/PS1 mouse brain

Both activated astrocytes and microglia have been shown
to limit deposits of Αβ through phagocytosis and
degradation [24, 25]. We addressed whether AQP4
deficiency altered Αβ-related reactive gliosis in the
hippocampus and cerebral cortex of APP/PS1 mice at
12 months of age, using glial fibrillary acidic protein
(GFAP) and ionized calcium-binding adaptor molecule 1
(Iba-1) immunohistochemistry. Each Αβ plaque was surrounded by GFAP-IR astrocytes and Iba-1-IR microglia
in APP/PS1 mice. In contrast, a considerable portion of
Αβ plaques lacked GFAP-IR astrocytes surrounding in
AQP4−/−APP/PS1 mice (Fig. 4a, b). A decreased number
of Iba-1-IR microglia around Αβ plaques was also

observed, especially in the cerebral cortex (Fig. 4a).
Quantitative analysis revealed that AQP4−/−APP/PS1
mice had a decreased area percentage of GFAP expression compared with APP/PS1 mice, but the difference
was not significant for those of Iba-1 (Fig. 4c). Western
blot analysis also revealed that AQP4 deficiency significantly attenuated up-regulation of GFAP, but not Iba-1,
in the hippocampus and cortex of APP/PS1 mice, as
compared to WT and AQP4−/− mice (Fig. 4e, f ).
It has also been shown that, apart from reactive hypertrophy, a subpopulation of astrocytes undergo apoptosis
or atrophy in AD patients [26, 27] and transgenic AD
animal models [28, 29], due to chronic exposure to high
concentrations of Aβ. Therefore, we determined whether
the reduced reactive astrogliosis was a late stage

Xu et al. Molecular Neurodegeneration (2015) 10:58
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Fig. 2 AQP4 deficiency increased brain Aβ accumulation and CAA in 12 month-old APP/PS1 mice. a Aβ deposition in the hippocampus and
cortex stained by 6E10 and Thioflavin-S. b High magnification micrographs of 6E10 immunostaining. There was increased amyloid deposition
along small and large vessels in the brain parenchyma (arrowheads) and leptomeningeal vessels (stars) of AQP4−/−APP/PS1 mice, compared to
APP/PS1 controls. c The area percentage of 6E10-positive Aβ plaque load in the hippocampus (HC) and cerebral cortex. d The area percentage of
Thioflavin-S-positive Aβ plaque load in the hippocampus (HC) and cerebral cortex. e 6E10-immunoreactive (IR) intensity on the cortical vessels
and leptomeningeal vessels. f-i ELISA analysis of soluble and insoluble Aβ1–40 and Aβ1–42 in the brain samples. Data represent mean ± SEM from 5
to 6 mice (3–4 female, and 1–2 male) per group. The statistical analysis was performed by Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001

phenomenon of atrophy of astrocytes. The quantitative
analysis revealed that 12-month old AQP4−/−APP/PS1
mice had a smaller cellular surface area of GFAPpositive astrocytes surrounding plaques in the cerebral
cortex, when compared to age matching APP/PS1 controls (Fig. 4b, d).

Furthermore, different from reduced reactive gliosis at
12 months of age, 6.5 month-old AQP4−/−APP/PS1 mice
exhibited increases in reactive gliosis, as well as Αβ load,
in the hippocampus and cortex, when compared with
APP/PS1 controls (Additional file 2: Figure S2). Together, these data suggest that both reactive gliosis and

Xu et al. Molecular Neurodegeneration (2015) 10:58
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Fig. 3 AQP4 deficiency did not alter expression of brain Aβ formation and degradation-related proteins in 12 month-old APP/PS1 mice.
a Representative bands of Western bolt and b densitometry analysis of protein levels of APP and its proteolytic amyloidogenic fragments.
c Representative bands of Western bolt and d densitometry analysis of protein levels of the biochemical components involved in the
amyloid production (BACE1 and PS1) and degradation (IDE and NEP). Data represent mean ± SEM from 5 to 6 mice (3–4 female, and 1–2
male) per group. The statistical analysis was performed by Student’s t-test

astrocyte atrophy peaked earlier in AQP4−/−APP/PS1
mice due to acceleration of AD pathology.
Activated astrocytes and microglia facilitate Αβ clearance, but also mediate inflammation via cytokine production. Thus, reactive gliosis may play a double-edged
role in the AD pathology [30, 31]. Previous studies have
shown that AQP4 is involved in the release of cytokines
by activated astrocytes [19, 20]. Therefore, we examined
whether the attenuation of reactive astrogliosis affected
the production of inflammatory factors in the hippocampus and cortex of 12-month AQP4−/−APP/PS1
mice. APP/PS1 mice had significantly higher levels of
interleukin-1 beta (IL-1β), and higher levels, although
nonsignficant, of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) than AQP4−/−APP/PS1 mice
(Fig. 4g). There was no difference in baseline levels of
IL-1β, IL-6 and TNF-α between WT and AQP4−/−
controls.

in age-matching APP/PS1 mice, GFAP-positive astrocytes
adjacent to Aβ plaques exhibited hypertrophic feature
with obvious LRP1 expression (Fig. 5a). The subsquent
quantitative analysis revealed that AQP4−/−APP/PS1 mice
had decreases in the area percentage of LRP1 labeling
or LRP1 and GFAP double labeling within a radius of
100 μm to the plaque border, compared with APP/
PS1 mice (Fig. 5b, c). However, the area percentage
of LRP1 positive and GFAP negative was not different
each other (Fig. 5d), further suggesting that astrocyte
atrophy is a key factor for reduced LRP1 expression
surrounding Aβ plaques in AQP4 −/− APP/PS1 mice.
In addition, hippocampal and cortical neurons highly
expressed LRP1, which was not affected by AQP4 deficiency (Additional file 3: Figure S3A, S3C). Western
blot also showed that brain LRP1 protein levels were
similar between AQP4−/− APP/PS1 mice and APP/
PS1mice (Additional file 3: Figure S3B, S3D).

Atrophic astrocytes surrounding Aβ plaques decreased
LRP1 expression in AQP4−/−APP/PS1 mice

AQP4 deficiency exacerbated decreases in synaptic
protein expression and BDNF production in APP/PS1
mouse brain

Low density lipoprotein receptor-related protein-1 (LRP1)
is expressed by multiple brain cell types, with an important role in ISF soluble Αβ uptake and clearance across the
blood–brain-barrier [32, 33]. Our previous studies have
shown that AQP4 deficiency reduces uptake of Αβ by
cultured astrocytes, which is associated with decreased
up-regulation of LRP1 [18]. Consistently, we demonstrated that GFAP-positive astrocytes located around
the amyloid plaques underwent atrophy with very low
and even undetectable levels of LRP1 expression in 12month old AQP4−/−APP/PS1 mice (Fig. 5a). In contrast,

Synaptic impairment in the hippocampus and cerebral
cortex is a main pathological basis for cognitive impairment in AD [2]. Both synaptophysin (SYP) and postsynaptic density protein-95 (PSD-95) are particularly
vulnerable to the toxic effects of Αβ, and their loss correlates with cognitive decline in AD [34–36]. Therefore,
we determined whether genetic deletion of AQP4 in
APP/PS1 mice advanced cognitive impairment was associated with more severe impairment of SYP and PSD-95.
Deletion of AQP4 in 12-month old APP/PS1 mice

Xu et al. Molecular Neurodegeneration (2015) 10:58
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(See figure on previous page.)
Fig. 4 AQP4 deficiency increased astrocyte atrophy with attenuation of reactive gliosis and neuroinflammation in 12 month-old APP/PS1 mice. a
GFAP positive reactive astrogliosis was significantly attenuated in the hippocampus and cerebral cortex of AQP4−/−APP/PS1 mice compared with
APP/PS1 controls. A mild reduction of iba-1 positive reactive microgliosis also occurred in AQP4−/−APP/PS1 mouse brain. b The high magnification
images showing that Congo Red positive plaques were surrounded by activated GFAP-positive astrocytes, displaying morphological features of
hypertrophy, in APP/PS1 mice. In contrast, astrocytes adjacent to plaques exhibited atrophy with weak GFAP expression in AQP4−/−APP/PS1 mice.
The reactive microgliosis around plaques was mildly reduced in AQP4−/−APP/PS1 mice, compared that in APP/PS1 controls. c The percentage of
GFAP or Iba-1 positive area in the hippocampus and cortex. d GFAP-positive surface area per astrocyte and Iba-1-positive surface area per microglial
cell surrounding Aβ plaques within the cortex. e Representative bands of Western bolt and f densitometry analysis of GFAP and Iba-1 protein levels in
the hippocampus and cortex. g ELISA analysis of IL-1β, IL-6 and TNF-α levels in the hippocampus and cortex. Data represent mean ± SEM from 5 to 6
mice (3–4 female, and 1–2 male) per group. Data in Fig. 4c and d were analyzed by Student’s t-test and in Fig. 4f and g by ANOVA with post hoc
Student-Newman-Keuls test. *P < 0.05; **P < 0.01; ***P < 0.001

Fig. 5 AQP4 deficiency decreased LRP1 expression by astrocytes surrounding Aβ plaques in APP/PS1 mice. a Activated GFAP-positive (green)
astrocytes surrounding plaque-like structures (blue) clearly expressed LRP1 (red) (arrowheads) in 12-month old APP/PS1 mice. In contrast, in
age-matching AQP4−/−APP/PS1 mice, GFAP-positive astrocytes around plaques were atrophy with very low immunofluorescent staining of LRP1
(arrowheads). Some cells negative for GFAP (stars), expressed LRP1 in the both gene-type brains. b The percentage of LRP1 positive area within a
radius of 100 μm to the plaque border. c The percentage of LRP1 and GFAP double positive area. d The percentage of LRP1 positive, but GFAP
negative area. Data represent mean ± SEM from 5 to 6 mice (3–4 female, and 1–2 male) per group. The statistical analysis was performed by
Student’s t-test. ***P < 0.001
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significantly exacerbated loss of SYP and PSD-95 in the
hippocampus and cerebral cortex as revealed by both
immunohistochemistry (Fig. 6a, b) and Western blot
analyses (Fig. 6c, d).
In addition, brain-derived neurotrophic factor (BDNF)
is a key regulator of neuronal survival and synaptic plasticity that are required for the long-term learning and
memory [37]. Aβ accumulation has been implicated in
decreased BDNF levels by inhibiting activation of CREB,
a transcription factor that regulates BDNF expression
[38]. Decreased production of BDNF, in turn, exacerbates Aβ-related neurodegeneration in late-onset AD
[39]. Consistently, 12-month old AQP4−/−APP/PS1 mice
had lower levels of BDNF in the hippocampus and cerebral cortex, when compared to APP/PS1 controls, as revealed by Western blot (Fig. 7a, b) and ELISA (Fig. 7c).
Impaired AQP4 polarization during the pathological
progression of APP/PS1 mice

In the health brain, AQP4 is highly expressed in astrocyte processes abutting cerebral microvessels or pia,
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while its density is comparatively low at astrocyte membrane facing neuropil regions [40]. However, under various pathological conditions, reactive astrogliosis causes
mislocalization expression of AQP4, subsequently impairs its polarity at the perivascular endfoot processes
and glial limitans beneath the pia mater [3, 10, 12, 41].
Therefore, we investigated whether this pathological
change would also happen during the pathological progress of APP/PS1 mouse brain. The immunohistochemical results showed that AQP4 expression was highly
polarized in the brain of WT mice at 3, 6.5 and
12 months of age, characterized by high intensity of
AQP4-IR products surrounding large vessels and microvessels or facing pia maters, and very low intensity in
the adjacent parenchyma. AQP4 expression was slightly
increased at the regions immediately abutting large vessels, microvessels and pia maters as well as correspondingly adjacent parenchymal domains in 3-month-old
APP/PS1 mice that had no Aβ plaque disposition in the
brain. AQP4 expression was significantly increased at
parenchymal domains, particularly around Aβ plaques,

Fig. 6 AQP4 deficiency exacerbated decreases in SYP and PSD-95 in 12-month-old APP/PS1 mice. a SYP and PSD-95 expression was markedly
decreased in the hippocampus and cerebral cortex of AQP4−/−APP/PS1 mice, compared to APP/PS1 mice. b The percentage of SYP/PSD-95
positive area in the hippocampus and cortex. c Representative bands of Western bolt and d densitometry analysis of SYP and PSD-95 protein
levels in the hippocampus and cortex. Data represent mean ± SEM from 5 to 6 mice (3–4 female, and 1–2 male) per group. The statistical analysis
was performed by ANOVA with post hoc Student-Newman-Keuls test. *P < 0.05; **P < 0.01; ***P < 0.001
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Fig. 7 AQP4 deficiency promoted decreases in BDNF production in
12-month old APP/PS1 mice. a Representative bands of Western bolt
and b densitometry analysis of BDNF levels in the hippocampus and
cortex. c ELISA analysis of BDNF levels in the hippocampus and cortex.
Data represent mean ± SEM from 5 to 6 mice (3–4 female, and 1–2
male) per group. The statistical analysis was performed by ANOVA
with post hoc Student-Newman-Keuls test. *P < 0.05; **P < 0.01;
***P < 0.001

but unchanged at perivascular domains of 6.5 and
12 month-old APP/PS1 mice. In addition, AQP4 immunoreactivity was significantly increased at the cerebral
pia surface, as well as the subpial region (Fig. 8a, b). No
AQP4 immunoreactive signal was observed in the brain
of AQP4−/− mice and AQP4−/−APP/PS1 mice (Fig. 8c).
The selective localization of AQP4 to vessels or pia
maters was disrupted in APP/PS1 mice at 6.5 and
12 months of age, as confirmed by the quantitative data
of AQP4 polarization (Fig. 8d-f ).

Discussion
Aβ accumulation and aggregation in the extracellular
space of the brain is a pathological hall mark of AD. Aβ
peptides in the ISF aggregate into higher-order species,
such as soluble oligomers and insoluble amyloid plaques,
in a concentration-dependent manner. Thus, clearance
of accumulated Aβ from the brain parenchyma is a potentially promising therapeutic strategy to delay or even
counter Aβ pathology and AD progression [42, 43].
AQP4 is localized to astrocyte processes neighboring
cerebral microvessels or pia in a highly polarized manner. This expression feature has been shown to facilitate
the efficient clearance of ISF solutes, such as Aβ and
Tau, from the brain parenchyma [3, 5]. In the present
study, utilizing AQP4−/−APP/PS1 mice, we have provided
direct evidence for the involvement of AQP4 in Aβrelated pathophysiology. Long-term deficiency of AQP4
increases brain Aβ plaque deposits, CAA, synaptic protein
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damage and cognitive dysfunction in APP/PS1 mice. Exacerbated Aβ accumulation in AQP4−/−APP/PS1 brain also
increases astrocyte atrophy with decreases in LRP1 expression, which in turn would reduce the efficiency of Aβ
clearance from the brain. Atrophic astrocytes may attenuate their proinflammatory roles, while also reduce BDNF
production, thus potentially playing a double-edge role on
synaptic degeneration (Fig. 9). These results suggest that
the overall contribution of AQP4 in the AD-like pathophysiology of APP/PS1 mice serves a protective function,
highlighting a potential role of AQP4 as a therapeutic target for AD.
Accumulating evidence supports the notion that the
glial water channel AQP4 is not only responsible for
maintaining brain water homeostasis, but also involved
in various biological functions of astrocytes such as
regulation of extracellular space volume, potassium buffering, calcium signal transduction, neuronal excitability
and synaptic plasticity under baseline conditions [40, 44].
For example, deletion of AQP4 in mice impairs BDNFdependent synaptic plasticity without alterations of synaptic protein expression in the intact brain [45]. Behavioral
analyses reveal that AQP4−/− mice have impairment in
memory consolidation, rather than short-term memory
[21, 45, 46]. The critical role of AQP4 in astrocyte functions is evenly evident in pathological conditions, including cerebral edema [47], intracerebral hemorrhage
[48], neuromyelitis optica [49], neuroinflammation [19],
and epilepsy [50]. In agreement with this view, the
present study revealed that deletion of AQP4 in APP/
PS1 mice, but no in WT mice, decreases SYP and PSD95 expression and BDNF production. Consistently, AQP4
deficiency in the intact mice only affects spatial learning
performance during the latter stages of the Morris maze
training. In contrast, AQP4 deficiency in APP/PS1 mice
causes longer escape latency during the entire training
periods. Specifically, deleterious effect of AQP4 deletion on the spatial memory performance in the Morris
maze as well as the Y-maze is observed in APP/PS1 mice,
but not in WT mice (Fig. 1d-g). These results suggest
that AQP4 deficiency increases the vulnerability of
memory-related structural and functional impairment
under AD-like pathology.
Aβ accumulation is a key pathological source for synaptic loss and cognitive impairment in AD patients and
transgenic mice [42, 43]. At very low levels, Aβ peptides
act as a normal signal molecule, preventing excessive activation of neurons. When the balance between brain Aβ
production and clearance is broken, aggregated Aβ in
the extracellular space gradually manifests its neurotoxic
effects, finally causing neurodegeneration and cognitive
impairment [51]. AQP4 deficiency exacerbates Aβ accumulation in the cortex and hippocampus of APP/PS1
mice, which is the main pathological factor for severe
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Fig. 8 AQP4 polarization was lost during the pathological progression of APP/PS1 mice. Representative AQP4 immunoreactive images of the
hippocampus a andcerebral cortex b of WT mice and APP/PS1 mice at age of 3, 6.5 and 12 months. From 3 to 12 months of age, WT mice
showed high AQP4 expression closely abutting the large vessels (black arrows), microvessels (green arrows) and pia surface (blue arrows), but low
AQP4 expression in the adjacent parenchyma (indicated by stars). In 3-month-old APP/PS1 mice that had no Aβ plaque disposition, AQP4
expression was slightly increased at the regions immediately abutting large vessels, microvessels and pia maters as well as correspondingly adjacent
parenchymal domains. At 6.5 and 12 months of age, AQP4 was markedly increased at parenchymal domains surrounding Aβ plaques, but not
significantly changed at the perivascular domains. c There was no immunoreactive signal for AQP4 in the hippocampus of AQP4−/− mice
and AQP4−/−APP/PS1 mice. Brain sections from WT mice were also immuno-negative when the AQP4 antibody were omitted and
replaced with an equivalent concentration of normal rabbit serum. Congo Red positive plaques were only observed in the AQP4−/−APP/
PS1 hippocampus. Quantitative analyses of the AQP4 polarization abutting large vessels d (n = 16–20 per mouse), microvessels e (n = 16–20 per
mouse) and pia maters f (n = 4 per mouse). Data represent mean ± SEM from 5 to 6 mice (3–4 female, and 1–2 male) per group. The statistical
analysis was performed by Student’s t-test. ***P < 0.001

spatial memory deficits, although loss of AQP4 physiological functions itself is also involved in alterations in
cognitive performance.
The generation of Aβ from APP is controlled by αsecretase mediated non-amyloidogenic pathway and β,
γ-secretase-mediated amyloidogenic pathway [22]. However, APP levels are not different between the two

genotype littermates, suggesting that AQP4 deficiency
does not affect Aβ production. Also, AQP4 deficiency
does not alter expression levels of proteins associated
with Aβ formation and degradation. Therefore, we believe that increased Aβ load in AQP4−/−APP/PS1 brain
is due to more severe impairment of Aβ clearance, via
the following mechanisms.
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Fig. 9 Schematic diagram of AQP4 mitigating plaque pathogenesis
in APP/PS1 mice. We propose that genetic deletion of AQP4 that
mediates paravascular interstitial Aβ clearance in APP/PS1 mice
results in accelerated accumulation of Aβ in brain parenchyma and
cerebral blood vessels, and subsequently improves synaptic
degeneration and astrocyte atrophy. In addition, extensive reactive
astrocytes would impair AQP4 polarity, thus impairing the efficiency
Aβ clearance from paravascular space into blood and CSF

First, the lack of AQP4 mediated paravascular pathways of Aβ clearance could be a critical factor for
heightened Aβ accumulation in AQP4−/−APP/PS1 brain.
It is known that AQP4 mediated rapid transport of
intercellular water serves as a main “driving force” for
clearance of interstitial solutes, including Aβ, from the
brain parenchyma into the blood and CSF [3–6]. Deletion of the AQP4 gene damages rapid water transportdependent clearance of 125I-Aβ1–40 from brain parenchyma to the blood and CSF [5]. In the present study,
AQP4−/−APP/PS1 mice show increases in amyloid
plaque deposit in the hippocampus and cerebral cortex
and high concentrations of Aβ1–40 and Aβ1–42 in brain
protein extraction, compared with APP/PS1 transgenic
mice. AQP4 deficiency in APP/PS1 mouse brain improving amyloid load within the walls of brain vessels and
surfaces of pia mater further supports a facilitating role
of AQP4 in the perivascular glymphatic drainage of Aβ.
Astrocyte atrophy, with attenuation of reactive gliosis
and low expression of LRP1, may be another critical factor for heightened Aβ accumulation in AQP4−/−APP/
PS1 brain. Reactive astrogliosis surrounding Αβ plaques
has been shown to limit plaque growth. Attenuating
astrocyte activation, by deletions of GFAP and vimentin,
accelerates amyloid plaque load in APP/PS1 mice [13].
By contrast, enhancing astrocyte lysosome biogenesis
with transcription factor EB, a master regulator of lysosome biogenesis, facilitates Aβ clearance in APP/PS1
mice [25]. The present pathological analyses have shown
that reactive hypertrophic astrocytes, with up-regulation
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of LRP1 and AQP4, surround Aβ plaques in 12-month
old APP/PS1 mice. This result is consistent with our
previous studies showing that activated cultured astrocytes increase both LRP1 and AQP4 expression in response to Aβ treatment [18]. LRP1 is shown to mediate
clearance mechanisms of brain Aβ, via either its uptake
into brain cells with subsequent degradation or its transport across the blood–brain-barrier into the periphery
[33]. Therefore, reactive astrogliosis may perform a
plaque-clearance effect via LRP1 binding Aβ, thereby decreasing the concentration of Aβ in the extracellular
space, and subsequently attenuating Aβ toxicity. However, AQP4 deficiency alters these effects of reactive astrocytes, exacerbating Aβ plaque deposit and soluble Aβ
accumulation. Increased Aβ load improves its toxicity
on astrocytes, resulting in astrocyte atrophy with downregulation of LRP1. This, in turn, affects Aβ clearance,
thus forming a vicious cycle between Aβ accumulation
and astrocyte damage in the AD-like pathology.
The present results also reveal that genetic deletion of
AQP4 has a tendency to reduce the number of microglia
surrounding Aβ plaques in 12 month-old APP/PS1 mice.
Serving as macrophage-like cells in the CNS, undoubtedly activated microglia perform a scavenging effect on
Aβ plaque and degenerated neuronal components [31].
Mildly reduced microgliosis may also be a contributor to
increased Aβ load in AQP4−/−APP/PS1 mouse brain.
The attenuation of microglia activation could be a consequence of reduced astrogliosis, since microglia do not
express AQP4. In the acute stages of neurotrauma,
stroke and neuroinflammation, microglia are activated
and subsequently evoke astrocyte activation via the release of pro-inflammatory cytokines and chemokines. In
the chronic stages, activated astrocytes also produce
similar cytokines for self-regulation and for the regulation
of microglia [52]. This phenomenon creates a feedback
loop, allowing both microglia and astrocytes to regulate
one another. In agreement with the present finding, reduced reactive astrogliosis and microgliosis is also observed in AQP4−/− mice in experimental autoimmune
encephalomyelitis and after intracerebral injection of LPS
[19, 20]. AQP4 deletion impairs glial scar formation and
reduces neuroinflammation in the acute stage of posttraumatic impairment, but improves neurodegeneration
and reactive gliosis in the chronic stage, which could possibly be attributed to prolonged impairment of extracellular tau clearance along glymphatic paravascular pathways
[3]. Our studies also show that AQP4 deletion in APP/PS1
mice improves reactive astrogliosis at age of 6.5 months,
but attenuates astrogliosis at 12 months, which could be
due to astrocyte atrophy caused by increased Aβ accumulation. Together, these studies suggest the effect of AQP4
deletion on astrocyte reactivity depends on the types and
stages of neurological diseases.
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Additionally, previous studies have indicated that AQP4
has an intrinsic proinflammatory role during astrocyte activation [20]. This view is further supported by reduced
cytokine (IL-6 and TNF-α) secretion in AQP4−/− astrocyte
cultures exposed to LPS [19]. The present results also indicate that AQP4 knockout has a tendency to attenuate
glial inflammation in 12 month-old APP/PS1 brain,
reflected by significant decreases in IL-1β and nonsignficant decreases in IL-6 and TNF-α in hippocampal and
cerebral samples. Compared with IL-6, IL-1β is produced
by reactive astrocytes already in a very early stage of Aβ
deposition [52, 53]. Thus, reduced reactive astrocytes
could possibly be a key factor for ameliorating IL-1β increases in AQP4−/− APP/PS1 brain. Aside from reactive
astrocytes and microglia, IL-6 and TNF-α are also produced by degenerative neurons [54, 55]. Thus, more severe neurodegeneration in AQP4−/−APP/PS1 mice may
increase neuronal IL-6 and TNF-α expression, leading to
a compensatory role for reduced IL-6 and TNF-α produced by reactive glia. Although the long term deletion of
AQP4 has a tendency to attenuate the glial inflammation
that has detrimental effects on the brain, it should be
noted that it impairs beneficial effects of reactive gliosis,
such as up-regulation of BDNF expression [56], facilitating
Aβ clearance and restricting the growth of Aβ plaques
[13, 25, 56]. This further exacerbates synaptic and cognitive impairments in APP/PS1 mice.
Activated astrocytes with overexpression of AQP4 in
the vicinity of amyloid plaque may facilitate Aβ removal
and limit plaque growth in APP/PS1 mice. Nevertheless,
loss of perivascular AQP4 polarization would impair
perivascular clearance of Aβ, causing amyloid deposition
within the walls of cortical and pial vessels [7, 57].
AQP4 is highly expressed in astrocyte processes abutting
cerebral microvessels or pia, while its density is comparatively low at astrocyte membrane facing neuropil regions [8, 40]. Several studies have suggested that AQP4
mediating drainage of ISF and solutes from brain parenchyma along vascular walls are dependent on the perivascular AQP4 polarization [5, 12]. In deed, loss of
perivascular AQP4 polarization coincides with impaired
clearance of exogenous Aβ and Tau from the cerebral
cortex [3, 6]. In the present study, we found that the polarized expression of AQP4 in perivascular astrocyte
endfeet, as well as glial limitans along the cortical surface, was progressively disrupted during the neuropathological progress of APP/PS1 mice. This was mainly due
to widespread astrogliosis with marked upregulation of
AQP4 in the neuropil, especially those surrounding plaques. Although we have demonstrate that deletion of
AQP4 exacerbates CAA, further studies are necessary to
indentify the exact causal relationship between impaired
perivascular AQP4 polarization and vascular Aβ deposits
in APP/PS1 mice at the different ages. It is also
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necessary to investigate the effect of AQP4 deletion on
the onset of early AD-related cognitive deficit and Aβ
pathogenesis in APP/PS1 mice at younger age in
addition to 12 months of age. In addition, it has been
shown that paravascular Aβ clearance is regulated by the
sleep-wake cycle, which is disturbed in many patients
with AD [58]. It will be interesting to investigate
whether deletion of AQP4 may affect this pathway in
both physiological and pathological conditions.

Conclusions
In summary, the present study demonstrates that AQP4
attenuates brain Aβ accumulation and memory deficits
in APP/PS1 mice. AQP4 mediated clearance of soluble
Aβ from the brain parenchyma in AD pathology may
occur via two main mechanisms: the paravascular pathway and glial activation. It should be further addressed
the roles played by each in the various stages of AD.
Given the potentially proinflammatory features of AQP4,
effective dosage and treatment time-window of AQP4
receptor agonists in the treatment of AD need further
evaluation. Establishing whether its inflammatory sideeffects can be reduced by combined treatment with
non-steroidal anti-inflammatory drugs also needs further
investigation. Exploring these issues will be conducive to
providing theoretical and experimental basis for clinical
therapy of AD via targeting AQP4.
Methods
Ethics statement

Animal experiments were performed in accordance with
the recommendations in the Guide for the Care and Use
of Laboratory Animals of Nanjing Medical University.
All of the animals were handled according to approved
by the Institutional Animal Care and Use Committee
(NJMU) protocol 1210.
Mice

APP695/PS1-dE9 transgenic (APP/PS1) mice with a
C57BL/6 J background were obtained from Jackson
Laboratories. AQP4−/− mice in a CD1 genetic background
have been established in our laboratory [59] and successfully used for investigating roles of AQP4 in astrocyte
function and neuropsychiatric disorders [15–18, 21,
46, 48]. Adult APP/PS1 mice were crossed with female
AQP4−/− mice to produce AQP4+/−APP/PS1 mice. Female
and male AQP4+/−APP/PS1 mice were crossed to produce
AQP4+/−APP/PS1 and AQP4+/−APP/PS1−/− offspring,
which were then mated to generate AQP4+/+APP/PS1−/−
(WT) mice, AQP4+/+APP/PS1 (also named APP/PS1)
mice, AQP4−/−APP/PS1−/− (also named AQP4−/−) mice
and AQP4−/−APP/PS1 mice that are all of the same mixed
background (C57BL/6 J CD1). The mouse genotype was
identified using polymerase chain reaction, as previously
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described [59, 60] (Additional file 4: Figure S4). Following
weaning, same-sex littermates were housed 3–4 per cage,
until they were 11.5-12 month-old. One mouse per cage
was then randomly selected for behavioral testing. A subgroup of APP/PS1 mice and AQP4−/−APP/PS1−/− mice at
6.5 months was used for analyses of reactive astrogliosis
and Aβ plaque deposit. Several WT and APP/PS1 mice at
3, 6.5 and 12 months of age were used for analysis AQP4
polarization.
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paraffin. Sagittal brain sections were serially cut at 5 μm
using a paraffin slicing machine (Leica RM2135, Nussloch,
Germany), and collected form Lateral −0.96 to −1.92 mm
in the mouse brain atlas as landmarks [62]. Every tenth
section was collected as 1 set, and 10 sets per brain hemisphere were obtained. For biochemical analyses, mice
were euthanized by decapitation. The cerebral cortex and
hippocampus were promptly dissected. Tissues were
flash frozen in liquid nitrogen and stored at −80 °C
until analysis.

Y-maze test

The Y-maze test was conducted to evaluate the shortterm spatial working memory of the mice, as previously
described [61]. The test contains two, 5-min stages with
an interval of 2 h between evaluation periods. During
the first stage, the novel arm was blocked by a black baffle, allowing mice to only move in the other two arms.
During the second stage, the novel arm was open, and
mice could freely move throughout the three arms. The
percentage of time traveled in each arm, number of entries into each arm, and travelling speed was calculated.
Morris water maze

The Morris water maze task was performed to measure
long-term spatial learning and memory function, as described previously [16]. Training was conducted over 8
consecutive days, with 4 trials per day. During the first
two days, mice were trained to find a dark-colored cylindrical platform with a diameter of 10 cm, sitting 0.5 cm
above the water surface. Mice were not given the next
hidden platform tests if they had apparent motor and/or
visual deficits indicated by long escape latency (>50 s)
and low swimming speed (<75 mm/s). On the 3rd day,
the platform was moved to the opposite quadrant and
submerged 1 cm below the surface of the water. The escape latency, swimming distance and swimming speed
were analyzed. On day 9, the hidden platform was removed, allowing mice to swim in the pool for 60 s. The
percentage of total time spent in each quadrant, and the
number of crossing where the platform had been previously located, were analyzed.
Mouse activity in the aforementioned behavioral apparatuses was collected by a digital video camera connected to a computer-controlled system (Beijing Sunny
Instruments Co. Ltd, China). All tests were performed
by two independent experimenters, who were each blind
to the treatment schedule.
Section and tissue preparation

After anesthesia, mice were transcardially perfused with
0.9 % saline, followed by 4 % paraformaldehyde by perfusion pump (Cole-parmer, USA). Brains were dissected
mid-sagittallly, postfixed overnight at 4 °C, dehydrated
in a series of graded ethanol solutions then embedded in

Immunohistochemistry

Immunohistochemical staining was performed as previously described [16]. Briefly, one set of brain sections
per mouse were respectively incubated with one of the
following primary antibodies: rabbit anti-6E10 (1:1000;
Covance, Princeton, NJ, USA), mouse anti-GFAP (1:1000;
Millipore, Billerica, MA, USA), mouse anti-Iba-1 (1:500;
Wako, Osaka, Japan), mouse anti-SYP (1:1000; Millipore),
rabbit anti-PSD-95 (1:500; Abcam, Cambridge, MA,
USA), rabbit anti-LRP1 (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or rabbit anti-AQP4 (1:500;
Millipore) overnight at 4 °C. Following PBS rinsing, the
sections were incubated with biotinylated goat anti-mouse
or rabbit IgG (1:400) for 1 h at room temperature and
thereafter incubated with streptavidin-biotin-peroxidase
complex (Elite ABC Kit, Vector Laboratories, Burlingame,
CA, USA). All experimental conditions including incubation time of 3,3′-diaminobenzidine (DAB) staining were
kept in consistence with each other. In general the
antibody-bound peroxidase was visualized by incubating
sections for 3–4 min in 0.05 % DAB with H2O2 to avoid
that staining intensity could be saturated. Sections with
GFAP, Iba-1 or AQP4 immunostaining were counterstained by Congo Red.
Immunohistochemical controls were taken by omitting
the primary antibodies or replacing with an equivalent
concentration of either normal mouse serum or normal
rabbit serum. The immunostaining for AQP4 was also
performed on brain sections of AQP4−/− mice to exam
the specificity of the antibody. All sections were
immuno-negative.
Immunofluorescence

Paraffin-embedded tissue sections were deparaffinized
and hydrated through a series of graded ethanol solutions, followed by 0.1 M Tris, pH 7.6. Slices were
blocked for 1 h at room temperature with 3 % normal
goat serum, incubated with primary antibodies including
mouse anti-GFAP (1:500, Millipore) and rabbit antiLRP1 (1:200; Santa Cruz Biotechnology) overnight at 4 °C.
After extensive rinsing, sections were incubated for 2 h at
room temperature in a mixture of FITC-conjugated goat
anti-mouse IgG (1:150, Vector laboratories) and Texas
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Red-conjugated goat anti-rabbit IgG (1:150, Vector
Laboratories). The sections were washed for 3 × 5 min in
PBS containing 1.5 μM 4',6-diamidino-2-phenylindole
(DAPI, Invitrogen, Carlsbad, CA, USA) and then coverslipped with buffered PBS/glycerol.
ELISA Analysis

Cerebral cortex and hippocampus samples were homogenized and sonicated in ice-cold TBS buffer containing
0.5 mM PMSF, 0.5 mM benzamidine, 1.0 mM DTT and
1.0 mM EDTA, followed by centrifugation at 100,000 × g
for 1 h. Supernatants were set aside for measurements
utilizing soluble Aβ1–40 and Aβ1–42, IL-1β, IL-6, TNF-α
and BDNF. Pellets were re-suspended and further homogenized in 70 % formic acid (equal volume of TBS),
then centrifuged at 100,000 × g for 1 h. Formic acid supernatants were neutralized with 1 M Tris for insoluble
Aβ1–40 and Aβ1–42 analysis [63]. The above indexes were
quantified with ELISA kits from Invitrogen Corporation
according the manufacturer’s instructions.
Western blot

Cerebral cortex and hippocampus extracts were loaded
onto 10-16 % Tris/tricine SDS gels, and transferred to
nitrocellulose membranes before overnight incubation
with one of the following primary antibodies: rabbit
anti-APP (1:1000; Millipore), rabbit anti-Aβ1–42 (1:1000;
Sigma-Aldrich, Saint Louis, MO, USA) and mouse
anti-SAPPβ (1:1000; Sigma-Aldrich), mouse anti-CTFβ
(1:1500; Millipore), mouse anti-BACE1 (1:2000; Millipore), rabbit anti-PS1 (1:1000; Sigma-Aldrich), rabbit
anti-NEP (1:1000; Millipore), rabbit anti-IDE (1:1000;
Abcam, Cambridge, MA, USA), mouse anti-GFAP
(1:2000; Millipore), mouse anti-Iba-1 (1:500; Wako),
mouse anti-SYP (1:1500; Millipore), rabbit anti-PSD-95
(1:1000; Abcam), mouse anti-BDNF (1:500; SigmaAldrich) or rabbit anti-β-tubulin (1:3000; Sigma-Aldrich).
Horseradish peroxidase-conjugated secondary antibodies
(Vector Laboratories) were used, and bands were visualized using ECL plus detection system. β-tubulin was utilized as an internal control for protein loading and
transfer efficiency.
Quantitative analyses of plaque load and
immunohistochemistry

Sections were visualized using a digital microscope
(Leica Microsystems, Wetzlar, Germany) and captured
with constant exposure time, offset, and gain for each
staining marker. For analysis of the percentage area of
positive signal for Thioflavin-S, 6E10, GFAP, Iba-1,
LRP1, SYP or PSD-95, the corresponding images of the
hippocampus, together with the cerebral cortex immediately dorsal to the hippocampus, were captured at × 100
magnification, and exported to Image-Pro Plus 6.0
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Analysis System (Media Cybernetics Inc., San Francisco,
CA, USA). The cerebral and hippocampal areas in each
section were manually delineated. The area of positive
signal was measured using the interest grayscale threshold analysis with constant settings for minimum and
maximum intensities for each staining marker as described previously [64]. The percentage area of positive
signal was calculated by dividing the area of positive signal to the total area in the region of interest.
For analysis of 6E10 expression on the CAA, crosssectional areas of GFAP or Iba-1 positive cells around
plaques, LRP1 expression around plaques, or AQP4
polarization, two images at 400× magnification were
randomly captured from the outer layers of the cortex
and the lacunosum moleculare layer of the hippocampus
on each brain section, respectively. The mean 6E10-IR
intensity along the walls of cortical and leptomeningeal
vessels was measured by Image-Pro Plus Software. The
cell surface area of GFAP-positive astrocytes or Iba-1
positive microglia with somata within 100 μm from the
plaque border was also measured. For analysis of AQP4
expression and localization, the mean AQP4-IR intensity
at the regions immediately abutting large vessels (diameter > 25 μm), microvessels (diameter < 10 μm) or pia maters and correspondingly adjacent parenchymal domains
was measured. Perivascular (or pia) AQP4 polarization
was obtained by comparing expression ratios of AQP4 at
perivascular (or pia surface) versus parenchymal domains
[6, 41]. For analysis of plaques related LRP1 expression,
the percentage of LRP1 positive area within a radius of
100 μm to the plaque border was measured on the immunofluorescent sections. The percentage of LRP1 and
GFAP double positive area and the percentage of LRP1
positive and GFAP negative area were also calculated.
Eight-nine brain sections in each set were averaged for
each mouse, and 5–6 mice were averaged for each genotype group. All quantification was done blind to animal
genotype.
Statistical analysis

All data were expressed as means ± SEM. Using SPSS
software, version 16.0 (SPSS Inc., USA), data for the
Morris water maze platform training were analyzed by
repeated-measures analysis of variance (ANOVA) followed
by Newman-Keuls post-hoc multiple comparison test.
Other data were analyzed by ANOVA, followed by
Newman-Keuls post-hoc multiple comparison test or Student’s t-test as indicated in the figure legends.

Additional files
Additional file 1: Figure S1. The examples of several antibodies
including APP, BACE1, PS1, and IDE, NEP and β-tubulin on the whole
membranes, and found that all these proteins were detected at the
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position of the corresponding molecular weight (indicated by arrowheads).
(TIF 1697 kb)
Additional file 2: Figure S2. AQP4 deficiency increased reactive
astrogliosis and Aβ plaque deposits in 6.5 month-old APP/PS1 mice. (A)
GFAP immunostaining counterstained with Congo Red. AQP4−/−APP/PS1
mice had more extensive reactive astrogliosis in the cerebral cortex and
hippocampus than APP/PS1controls. (B) Thioflavin-S staining showing Aβ
load in the cortex and hippocampus. (C) The percentage area of GFAP
positive. (D) The percentage area of thioflavin-S positive. Data represent
mean ± SEM from 5 mice (3 female, and 2 male) per group and analyzed
by Student’s t-test. *P < 0.05. (TIF 4322 kb)
Additional file 3: Figure S3. AQP4 deficiency did not affect LRP1
expression by neurons in APP/PS1 mice. (A) LRP1 immunohistochemistry.
High expression of LRP1 was localized to the cell membrane of pyramidal
neurons in 12-month old AQP4−/−APP/PS1 mice and APP/PS1 mice. Some
glial-like cells (inserted high magnification images) distal to the plaques
were also positive for LRP1 in the two genotype mice. (C) Quantitative
analysis of the percentage of LRP-1 positive area in the hippocampus and
cerebral cortex. (B) Western bolt and (D) densitometry analysis of LRP1
protein levels in the hippocampus and cortex. Data represent mean ± SEM
from 5–6 mice (3–4 female, and 1–2 male) per group. The statistical analysis
was performed by Student’s t-test. (TIF 3855 kb)
Additional file 4: Figure S4. Genotyping of mice. An example of PCR
analysis of AQP4 (the upper panel) and APPSwe (the low panel) mRNA
expression in a newborn litter that is generated by AQP4+/−APP/PS1+/+
and AQP4+/−APP/PS1−/− mice. We only detected APPSwe transgene,
because APPSwe transgene and PS1ΔE9 transgene are coexpressed
under the control of the mouse prion promoter (Jankowsky et al. [60]).
APP/PS1 transgene allele yields a 377-bp product; and wild type allele
has no product. AQP4 knockout homozygote allele yields a 320-bp
product; heterozygote allele yields 240-bp and 320-bp products; and
wild type allele yields a 240-bp product. In this litter, eleven mice
belong to the following 6 genotypes: AQP4+/+APP/PS1+/+ (mice 1 and
4), AQP4+/−APP/PS1−/− (mouse 2), AQP4+/−APP/PS1+/+ (mice 3, 8 and 9),
AQP4−/−APP/PS1+/+ (mice 5 and 6), AQP4−/−APP/PS1−/− (mice 7 and 10),
and AQP4+/+APP/PS1−/− (mouse 11). (TIF 2043 kb)
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